Arlene Siefker-Radtke  is a Professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center. Her research focus is on developing effective therapies in the treatment of urothelial cancer and other rare tumors of the bladder and upper tract. She is well-known for her novel clinical trial designs, development of novel agents and targets including immunotherapy and cytokine analogues, FGFR inhibitors, development of neoadjuvant chemotherapy, and expertise in treating even those most rare tumors of the bladder.